Article
High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy - 1 Feb 2012
Kubo Shuku, Tokumitsu Akane, Tomozawa Takanori, Kakuta Masayo, Yamashita Makoto
Abstract excerpt
Laninamivir octanoate (Inavir(®); Daiichi Sankyo, Tokyo, Japan) is an anti-influenza drug that provides complete treatment by a single inhalation. It works as a long-acting neuraminidase (NA) inhibitor by means of high and continuous exposure of laninamivir, its active metabolite, in the lungs of mice after intranasal administration. Even after 6 days after intranasal administration of 236 μg/kg laninamivir...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
